We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nordson Unit Launches Forte Series Fluid Dispensing System
Read MoreHide Full Article
Nordson ASYMTEK, a business unit of Nordson Corporation (NDSN - Free Report) recently unveiled its Forte Series fluid dispensing system. Built in Nordson ASYMTEK’s Canvas software, the Forte Series brings in enhanced accuracy fluid dispensing with improved throughput and productivity required for handling various applications. These include electro-mechanical assembly, flex circuit and printed circuit board assembly, MEMS, and encapsulation.
Featuring latest electrical and mechanical architectures, and a stable chassis, the Forte Series is designed to provide units per hour (UPH) gain of 20-50% increased productivity through better motion control. Its dual-valve-ready design enables users to operate two high-frequency IntelliJet Jetting Systems at the same time. This helps to reduce half of dispense time, improving UPH and quality outcomes.
Notably, the new interface, delivered by the Canvas software, helps in simplifying programming apart from offering strong insight and control over the dispensing process. In addition, the graphical programming allows users to develop their program online or offline, scan a workpiece, and simulate dispensing outcomes on a virtual canvas. The launch will offer users a complete solution for high quality, reliable and low-maintenance dispensing.
Existing Business Scenario
Nordson has been grappling with adverse impact of rising costs and expenses. It is worth mentioning here that the company recorded 1.2% year-over-year rise in selling and administrative expenses in the second quarter of fiscal 2019 (ended Apr 30, 2019). If unchecked, higher costs and operating expenses will prove detrimental to its margins and profitability.
Also, it is exposed to geopolitical risks and headwinds arising from unfavorable movements in foreign currencies. As a matter of fact, in fiscal 2019 (ending October 2019), unfavorable foreign currency movements are likely to have an adverse impact of 2% on sales growth.
Moreover, the company faces strong competition in all product categories and subcategories. Notably, its major peers include Graco Inc. (GGG - Free Report) , IDEX Corporation (IEX - Free Report) and Applied Industrial Technologies, Inc. (AIT - Free Report) .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Nordson Unit Launches Forte Series Fluid Dispensing System
Nordson ASYMTEK, a business unit of Nordson Corporation (NDSN - Free Report) recently unveiled its Forte Series fluid dispensing system. Built in Nordson ASYMTEK’s Canvas software, the Forte Series brings in enhanced accuracy fluid dispensing with improved throughput and productivity required for handling various applications. These include electro-mechanical assembly, flex circuit and printed circuit board assembly, MEMS, and encapsulation.
Featuring latest electrical and mechanical architectures, and a stable chassis, the Forte Series is designed to provide units per hour (UPH) gain of 20-50% increased productivity through better motion control. Its dual-valve-ready design enables users to operate two high-frequency IntelliJet Jetting Systems at the same time. This helps to reduce half of dispense time, improving UPH and quality outcomes.
Notably, the new interface, delivered by the Canvas software, helps in simplifying programming apart from offering strong insight and control over the dispensing process. In addition, the graphical programming allows users to develop their program online or offline, scan a workpiece, and simulate dispensing outcomes on a virtual canvas. The launch will offer users a complete solution for high quality, reliable and low-maintenance dispensing.
Existing Business Scenario
Nordson has been grappling with adverse impact of rising costs and expenses. It is worth mentioning here that the company recorded 1.2% year-over-year rise in selling and administrative expenses in the second quarter of fiscal 2019 (ended Apr 30, 2019). If unchecked, higher costs and operating expenses will prove detrimental to its margins and profitability.
Also, it is exposed to geopolitical risks and headwinds arising from unfavorable movements in foreign currencies. As a matter of fact, in fiscal 2019 (ending October 2019), unfavorable foreign currency movements are likely to have an adverse impact of 2% on sales growth.
Moreover, the company faces strong competition in all product categories and subcategories. Notably, its major peers include Graco Inc. (GGG - Free Report) , IDEX Corporation (IEX - Free Report) and Applied Industrial Technologies, Inc. (AIT - Free Report) .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>